Key result
High ANGPTL4 expression linked to ~40% worse overall survival and advanced features across multiple cancers.
Why the study?
Despite numerous studies suggesting the involvement of ANGPTL4 in cancer, its definitive role across various cancer types remains unclear.
Is increased ANGPTL4 expression associated with worse prognosis and tumor progression in cancer patients?
Meta-Analysis (n=3,268)
Is increased ANGPTL4 expression associated with worse prognosis and tumor progression in cancer patients?
Increased ANGPTL4 expression is associated with worse overall survival and tumor progression across various cancers, suggesting it as a potential therapeutic target.
Answers are grounded in this paper and cite their sources.
May refine prognostic stratification across cancers; extends observational data but leaves therapeutic targeting unproven.
BACKGROUND: Angiopoietin-like protein 4 (ANGPTL4) plays a crucial role in processes such as angiogenesis, inflammation, and metabolism. Despite numerous studies suggesting its involvement in cancer, a definitive role remains unclear. We introduce the first comprehensive meta-analysis and pan-cancer bioinformatics study on ANGPTL4, aiming to unravel its implications across various cancer types. METHODS: Moderate-to high-quality observational studies were retrieved from PubMed, Scopus, and Embase. A meta-analysis was conducted using the R package "meta." Survival analysis was performed using GEPIA2 and TIMER2.0. Immune infiltration, mutational burden, and drug resistance analyses was done via GSCAlite. Co-expression and gene set enrichment analyses (GSEA) were carried out using cBioportal and enrichr, respectively. RESULTS: Increased ANGPTL4 expression was linked to worse tumor grade (OR = 1.51, P = 0.023), stage (OR = 2.42, P < 0.001), lymph node metastasis (OR = 1.76, P = 0.012), vascular invasion (OR = 2.16, P = 0.01), and lymphatic invasion (OR = 2.20, P < 0.001). Furthermore, ANGPTL4 expression was linked to worse OS (HR = 1.40, 95% CI: 1.29,1.50, P = 0.0001). Single gene level analysis revealed that ANGPTL4 upregulated epithelial-to-mesenchymal transition (EMT) in 23 different cancers. Immune infiltration varied between cancer types, but increased infiltration of cancer-associated fibroblasts was observed in most cancers. Mutation analysis revealed increased alterations in TP53 and CDKN2A in cohorts with ANGPTL4 alterations. GSEA of co-expressed genes revealed involvement in hypoxia, EMT, VEGF-A complex, TGF-B pathways, and extracellular matrix organization. CONCLUSIONS: ANGPTL4 plays a significant role in tumor progression via its positive regulation of EMT and angiogenesis, while possibly harboring a TGF-B dependent role in systemic metastasis. Therefore, ANGPTL4 is a suitable target for future drug development.
No takes yet. Share an insight, caveat, or question.
Younis et al. (2025) conducted a meta-analysis in Cancer (n=3,268). High ANGPTL4 expression vs. Low ANGPTL4 expression was evaluated on Overall survival (HR 1.40, 95% CI 1.29-1.50, p=0.0001). High ANGPTL4 expression was associated with worse overall survival and advanced clinicopathological features across multiple cancer types.
Synapse has enriched 10 related papers. Consider them for comparative context: